EcoDrugPlus

Protein Kinase C, Delta A

Ensembl ID : ENSDARG00000009208
Gene Symbol: PRKCDA
42 Enzyme and pathways 5 Cross references
207 Possible Orthologues:

Protein Kinase C, Delta B

Ensembl ID : ENSDARG00000070651
Gene Symbol: PRKCDB
5 Cross references
204 Possible Orthologues:

Protein Kinase C, Epsilon A

Ensembl ID : ENSDARG00000003008
Gene Symbol: PRKCEA
16 Enzyme and pathways 5 Cross references
251 Possible Orthologues:

Protein Kinase C, Epsilon B

Ensembl ID : ENSDARG00000069928
Gene Symbol: PRKCEB
5 Cross references
268 Possible Orthologues:

Protein Kinase C, Eta, A

Ensembl ID : ENSDARG00000018382
Gene Symbol: PRKCHA
7 Enzyme and pathways 5 Cross references
220 Possible Orthologues:

Protein Kinase C, Eta, B

Ensembl ID : ENSDARG00000043243
Gene Symbol: PRKCHB
5 Cross references
161 Possible Orthologues:

Protein Kinase C, Iota

Ensembl ID : ENSDARG00000021225
Gene Symbol: PRKCI
12 Enzyme and pathways 5 Cross references
270 Possible Orthologues:

Protein Kinase C, Theta

Ensembl ID : ENSDARG00000034173
Gene Symbol: PRKCQ
21 Enzyme and pathways 5 Cross references
205 Possible Orthologues:

Protein Kinase C, Zeta

Ensembl ID : ENSDARG00000043332
Gene Symbol: PRKCZ
15 Enzyme and pathways 5 Cross references
205 Possible Orthologues:

Protein Kinase D1

Ensembl ID : ENSDARG00000075949
Gene Symbol: PRKD1
4 Enzyme and pathways 5 Cross references
214 Possible Orthologues:

Protein Kinase D3

Ensembl ID : ENSDARG00000079967
Gene Symbol: PRKD3
4 Enzyme and pathways 5 Cross references
218 Possible Orthologues:

Protein Kinase, Dna-Activated, Catalytic Subunit

Ensembl ID : ENSDARG00000075083
Gene Symbol: PRKDC
7 Enzyme and pathways 5 Cross references
187 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).